New 90-minute tests to aid winter fight against coronavirus and flu

The announcement follows a leak showing regular care home testing has been delayed

Clea Skopeliti
Monday 03 August 2020 08:10
Comments
Oliver Dowden says airport testing is 'not silver a bullet'

Two tests that can diagnose the coronavirus and the flu within 90 minutes are set to be introduced in hospitals, care homes and laboratories as the country prepares to face the pandemic in winter.

Nearly half a million of the LamPORE swab tests will be rolled out to adult care homes and laboratories from next week, with millions more to be made available in coming months.

The swab and DNA tests will aid doctors and the NHS test-and-trace system to differentiate between the viruses, allowing those with Covid-19 to effectively self-isolate.

Some 5,000 DNA test machines, which analyse nasal swabs, will be issued to NHS hospitals from September and are expected to provide 5.8 million tests later this year. The machines, supplied by DnaNudge, are already in use in eight London hospitals.

The health secretary, Matt Hancock, said: “Millions of new rapid coronavirus tests will provide on-the-spot results in under 90 minutes, helping us to break chains of transmission quickly.

“The fact these tests can detect flu as well as Covid-19 will be hugely beneficial as we head into winter, so patients can follow the right advice to protect themselves and others."

Mr Hancock thanked DnaNudge and Oxford Nanopore for the "excellent work" they have done to "push forward these life-saving innovations in coronavirus testing”.

The government announcement follows a leaked memo from Professor Jane Cummings, the government's adult social care testing director, which led the Department of Health and Social Care to deny it had dropped its commitment to regularly test care home residents throughout the summer.

Prof Cummings informed local authority leaders that "previously advised timelines for rolling out regular testing in care homes" were being affected by "unexpected delays", the Sunday Times reported.

Testing has been pushed back from 6 July to 7 September for older people and those with dementia, with a department spokesperson confirming it was having problems with "asymptomatic retesting".

Almost two-thirds of care homes are yet to have their first round of asymptomatic testing, according to the same newspaper.

Professor Chris Toumazou, co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London, said: “The DnaNudge team worked with incredible speed and skill during the peak of the pandemic to deliver this highly accurate, rapid Covid-19 test, which requires absolutely no laboratory or pipettes.”

Gordon Sanghera, CEO of Oxford Nanopore, said: “LamPORE has the potential to deliver a highly effective and, crucially, accessible global testing solution, not only for Covid-19 but for a range of other pathogens.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in